Clinical Trial Update: Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating perioperative tislelizumab in patients with resectable KRAS-mutated, nonsquamous non-small cell lung cancer; currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Cancer, Non-Small Cell | Phase 2 | Status: RECRUITING